AVROBIO Reports Third Quarter 2022 Financial Results and Provides Business Update

Author's Avatar
Nov 08, 2022

AVROBIO%2C+Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported financial results for the third quarter ended Sept. 30, 2022 and provided a business update.